# Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Source: https://onco.cc/trials/nct05435248/  
OnCo record `nct05435248` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HS-10375 in non-small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.

## Summary

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) is a phase 1/2 interventional study registered as NCT05435248 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 354 participants planned, started 2022-03-02 and due to reach its primary completion in 2025-03-31. Interventions recorded: HS-10375.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05435248
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10375 Monotherapy in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrolled: 354

## Sources

- ClinicalTrials.gov NCT05435248: https://clinicaltrials.gov/study/NCT05435248

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct05435248.json